ArticleOncology letters2018

Synergistic antitumor activity of low-dose c-Met tyrosine kinase inhibitor and sorafenib on human non-small cell lung cancer cells.

Ling Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.